Table 2.
MCo | MEx | FCo | FEx | pi | |
---|---|---|---|---|---|
HR, 1/min | 414 ± 9 | 400 ± 8 | 400 ± 12 | 397 ± 8 | 0.562 |
MAP, mmHg | 140.0 ± 5.1 | 138.3 ± 6.1 | 138.2 ± 5.0 | 142.2 ± 4.1 | 0.582 |
LVESP, mmHg | 156.5 ± 3.9 | 152.3 ± 8.2 | 148.7 ± 6.2 | 155.5 ± 5.7 | 0.380 |
LVEDP, mmHg | 3.3 ± 0.7 | 4.1 ± 1.5 | 3.7 ± 1.1 | 4.1 ± 1.1 | 0.861 |
dP/dtmax, mmHg/s | 9241 ± 397 | 9821 ± 667 | 9331 ± 565 | 10231 ± 654 | 0.785 |
dP/dtmin, mmHg/s | –12246 ± 432 | –12211 ± 670 | –12579 ± 655 | –13285 ± 487 | 0.521 |
LVEDV, μl | 229.9 ± 2.9 | 239.4 ± 4.6 | 210.1 ± 4.3 | 216.1 ± 5.2 | 0.689 |
LVESV, μl | 112.2 ± 1.8 | 101.6 ± 1.8ˆ* | 100.3 ± 4.0 | 83.8 ± 2.7ˆ# | 0.287 |
EF, % | 51.5 ± 1.1 | 57.5 ± 0.7ˆ* | 52.7 ± 1.9 | 61.1 ± 1.3ˆ# | 0.370 |
Values are means ± SEM. HR, heart rate; MAP, mean arterial pressure; LVESP, LV end-systolic pressure; LVEDP, LV end-diastolic pressure; dP/dtmax, maximal slope of the systolic pressure increment; dP/dtmin, maximal slope of the diastolic pressure decrement; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; EF, ejection fraction. ∗p < 0.05 vs. MCo, #p < 0.05 vs. FCo. pi: interaction value (factors: gender and exercise) of two-way analysis of variance (ANOVA).